TW552264B - Macrolide crystallines, process for preparation thereof and pharmaceutical composition comprising same - Google Patents

Macrolide crystallines, process for preparation thereof and pharmaceutical composition comprising same Download PDF

Info

Publication number
TW552264B
TW552264B TW087111867A TW87111867A TW552264B TW 552264 B TW552264 B TW 552264B TW 087111867 A TW087111867 A TW 087111867A TW 87111867 A TW87111867 A TW 87111867A TW 552264 B TW552264 B TW 552264B
Authority
TW
Taiwan
Prior art keywords
compound
formula
amorphous
crystallization
crystalline
Prior art date
Application number
TW087111867A
Other languages
English (en)
Chinese (zh)
Inventor
Cornelia Dosenbach
Maximilian Grassberger
Otto Hartmann
Amarylia Horvath
Jean-Paul Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW552264(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW552264B publication Critical patent/TW552264B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW087111867A 1997-06-30 1998-07-21 Macrolide crystallines, process for preparation thereof and pharmaceutical composition comprising same TW552264B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
TW552264B true TW552264B (en) 2003-09-11

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087111867A TW552264B (en) 1997-06-30 1998-07-21 Macrolide crystallines, process for preparation thereof and pharmaceutical composition comprising same

Country Status (31)

Country Link
US (1) US6423722B1 (enExample)
EP (1) EP0994880B1 (enExample)
JP (2) JP3880634B2 (enExample)
KR (1) KR100399765B1 (enExample)
CN (1) CN1139595C (enExample)
AR (1) AR017754A1 (enExample)
AT (1) ATE287410T1 (enExample)
AU (1) AU739211B2 (enExample)
BR (1) BR9810956A (enExample)
CA (1) CA2290412C (enExample)
CO (1) CO4940463A1 (enExample)
CZ (1) CZ297244B6 (enExample)
DE (1) DE69828692T2 (enExample)
DK (1) DK0994880T3 (enExample)
ES (1) ES2236922T3 (enExample)
GB (1) GB9713730D0 (enExample)
HU (1) HU227755B1 (enExample)
ID (1) ID24897A (enExample)
IL (1) IL132761A0 (enExample)
MY (1) MY118718A (enExample)
NO (1) NO312765B1 (enExample)
NZ (1) NZ500994A (enExample)
PE (1) PE97699A1 (enExample)
PL (1) PL192761B1 (enExample)
PT (1) PT994880E (enExample)
RU (1) RU2219181C2 (enExample)
SK (1) SK285665B6 (enExample)
TR (1) TR199903189T2 (enExample)
TW (1) TW552264B (enExample)
WO (1) WO1999001458A1 (enExample)
ZA (1) ZA985655B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
ATE450535T1 (de) * 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
CA2556993C (en) * 2004-04-08 2013-05-21 Novartis Ag Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
WO2006060615A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Non-hygroscopic and powdery amorphous pimecrolimus
CA2668134A1 (en) * 2006-11-06 2008-05-15 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of des-methylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2010512333A (ja) * 2006-12-07 2010-04-22 ヘルシン ヘルスケア ソシエテ アノニム 塩酸パロノセトロンの結晶及び非晶質形
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
EP3178824A1 (en) 2015-12-08 2017-06-14 Medichem, S.A. Process for preparing pimecrolimus
CA3060330A1 (en) * 2017-05-01 2018-11-08 Meda Pharma Gmbh & Co. Kg Process to convert crude ascomycin into purified pimecrolimus
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
CN121263183A (zh) 2023-04-06 2026-01-02 普利马克制药有限责任公司 吡美莫司用于治疗患者的特征在于牛津分级量表角膜染色评分为4或5分的干眼症的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
GB2084580B (en) 1980-10-01 1984-07-04 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
DK0433428T3 (da) 1989-07-10 1994-12-05 Chemferm Vof Hidtil ukendt stabil form af cephradin, fremgangsmåde til fremstilling deraf og mellemprodukter anvendt derved
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
WO1991013889A1 (en) * 1990-03-13 1991-09-19 Fisons Plc Immunosuppressive macrocyclic compounds
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
DE69217762T2 (de) 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
JP3808500B2 (ja) * 1994-02-22 2006-08-09 キューレータズ オブ ディ ユニバーシティ オブ ミズーリ 分離剤としての大環状抗生物質
CA2229718A1 (en) * 1995-08-24 1997-03-06 David J. Mathre Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
PE97699A1 (es) 1999-10-29
CN1139595C (zh) 2004-02-25
CZ297244B6 (cs) 2006-10-11
NO995909L (no) 1999-12-02
SK186699A3 (en) 2000-05-16
PL192761B1 (pl) 2006-12-29
ATE287410T1 (de) 2005-02-15
BR9810956A (pt) 2000-09-26
PL336719A1 (en) 2000-07-03
EP0994880A1 (en) 2000-04-26
HUP0003053A3 (en) 2003-03-28
CA2290412C (en) 2009-11-10
WO1999001458A1 (en) 1999-01-14
CA2290412A1 (en) 1999-01-14
DE69828692D1 (de) 2005-02-24
AR017754A1 (es) 2001-10-24
NZ500994A (en) 2001-08-31
NO312765B1 (no) 2002-07-01
NO995909D0 (no) 1999-12-02
JP3880634B2 (ja) 2007-02-14
DE69828692T2 (de) 2006-01-12
ZA985655B (en) 1998-12-30
CN1261365A (zh) 2000-07-26
TR199903189T2 (xx) 2000-06-21
KR20010020423A (ko) 2001-03-15
RU2219181C2 (ru) 2003-12-20
KR100399765B1 (ko) 2003-09-29
HU227755B1 (en) 2012-02-28
AU739211B2 (en) 2001-10-04
JP2001506279A (ja) 2001-05-15
JP4504323B2 (ja) 2010-07-14
GB9713730D0 (en) 1997-09-03
CO4940463A1 (es) 2000-07-24
IL132761A0 (en) 2001-03-19
SK285665B6 (sk) 2007-05-03
JP2006151999A (ja) 2006-06-15
AU8540998A (en) 1999-01-25
PT994880E (pt) 2005-06-30
ID24897A (id) 2000-08-31
DK0994880T3 (da) 2005-05-30
EP0994880B1 (en) 2005-01-19
HK1028597A1 (en) 2001-02-23
MY118718A (en) 2005-01-31
HUP0003053A2 (hu) 2001-02-28
CZ474099A3 (cs) 2000-04-12
US6423722B1 (en) 2002-07-23
ES2236922T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
CN103958491B (zh) 晶体的达格列净水合物
JP3880634B2 (ja) 結晶性マクロライドおよびその調製方法
US20120058236A1 (en) Sweetener composition comprising high solubility form of rebaudioside a and method of making
RS65585B1 (sr) Kristalna so 5-meo-dmt hidrobromid
CA2687841A1 (en) Stevioside polymorphic and amorphous forms, methods for their formulation, and uses
CN107400134A (zh) 嘌呤衍生物的结晶形式
US6613906B1 (en) Crystal modification
JP2026000991A (ja) 医薬組成物を製造する方法
RU2586117C2 (ru) Кристаллизация гидрохлорида эпирубицина
NO309607B1 (no) Ny krystallinsk form av morfin-6-glukuronid
TWI707851B (zh) 哌嗪化合物的新穎結晶
Bergren et al. Solid phases of delavirdine mesylate
MXPA99011294A (es) Macrolidos cristalinos y proceso para su preparacion
HK1028597B (en) Crystalline macrolides and process for their preparation

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent